Passage Bio reports ~$190M cash as of Dec 31, 2022; runway into H1 2025

Passage BIO, Inc.

Preliminary unaudited cash, equivalents and marketable securities of ~$190M at Dec 31, 2022.
Cash runway expected to fund operating expenses and capex into first half of 2025.
Update provided in January 9, 2023 corporate presentation; figures subject to audit.
No other financial results or guidance changes disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.